Liver Metastases Studies

TheraSphere for the Treatment of Liver Metastases

Principal Investigator:
Gregory A. Wiseman, M.D.
Secretary phone: 507-284-4399

Study Coordinator:
Teresa Mettler, RN
Phone: 507-538-0015

An Open Label Trial of TheraSphere in Patients with Liver Metastases from Primary Colorectal Cancer, Neuroendocrine or Non-Colorectal/Non-Neuroendocrine Cancer

Specific Aims:


  • To evaluate Progression Free Survival (PFS) following TheraSphere treatment, as determined by CT/MRI images according to RECIST criteria.
  • To evaluate the safety of TheraSphere treatment at doses of 120 ± 10% Gy in patients with metastatic disease to the liver.